299 related articles for article (PubMed ID: 32371550)
1. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Barzegar M; Mirmosayyeb O; Nehzat N; Sarrafi R; Khorvash F; Maghzi AH; Shaygannejad V
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32371550
[No Abstract] [Full Text] [Related]
2. Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.
Mallucci G; Zito A; Fabbro BD; Bergamaschi R
Mult Scler Relat Disord; 2020 Oct; 45():102414. PubMed ID: 32711296
[No Abstract] [Full Text] [Related]
3. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
4. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
[TBL] [Abstract][Full Text] [Related]
5. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Foerch C; Friedauer L; Bauer B; Wolf T; Adam EH
Mult Scler Relat Disord; 2020 Jul; 42():102180. PubMed ID: 32408155
[TBL] [Abstract][Full Text] [Related]
6. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 will change MS care forever - No.
Preziosa P; Rocca MA; Filippi M
Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
[No Abstract] [Full Text] [Related]
8. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Salama S; Ahmed SF; Ibrahim Ismail I; Alroughani R
Clin Neurol Neurosurg; 2020 Oct; 197():106203. PubMed ID: 32919242
[No Abstract] [Full Text] [Related]
9. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
Maghzi AH; Houtchens MK; Preziosa P; Ionete C; Beretich BD; Stankiewicz JM; Tauhid S; Cabot A; Berriosmorales I; Schwartz THW; Sloane JA; Freedman MS; Filippi M; Weiner HL; Bakshi R
J Neurol; 2020 Oct; 267(10):2790-2796. PubMed ID: 32494856
[TBL] [Abstract][Full Text] [Related]
10. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
11. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
Willis MD; Robertson NP
J Neurol; 2020 May; 267(5):1567-1569. PubMed ID: 32303837
[No Abstract] [Full Text] [Related]
12. Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic.
Naser Moghadasi A; Azadvari M; Sahraian MA
Arch Iran Med; 2020 Jul; 23(7):509-510. PubMed ID: 32657605
[No Abstract] [Full Text] [Related]
13. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
14. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
15. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
16. An Italian programme for COVID-19 infection in multiple sclerosis.
Sormani MP;
Lancet Neurol; 2020 Jun; 19(6):481-482. PubMed ID: 32359409
[No Abstract] [Full Text] [Related]
17. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
[No Abstract] [Full Text] [Related]
18. Multiple sclerosis following SARS-CoV-2 infection.
Palao M; Fernández-Díaz E; Gracia-Gil J; Romero-Sánchez CM; Díaz-Maroto I; Segura T
Mult Scler Relat Disord; 2020 Oct; 45():102377. PubMed ID: 32698095
[TBL] [Abstract][Full Text] [Related]
19. [EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].
Costa-Frossard L; Moreno-Torres I; Meca-Lallana V; García-Domínguez JM; En Representación Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autónoma de Madrid ERDGEEDCAM
Rev Neurol; 2020 May; 70(9):329-340. PubMed ID: 32329046
[TBL] [Abstract][Full Text] [Related]
20. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
